Cerus Corp (CU2.SG)
| Previous close | 1.5310 |
| Open | 1.5240 |
| Bid | 1.5270 x N/A |
| Ask | 1.5660 x N/A |
| Day's range | 1.5240 - 1.5240 |
| 52-week range | 1.1405 - 2.7630 |
| Volume | |
| Avg. volume | 66 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireCerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
CONCORD, Calif., April 18, 2024--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Simply Wall St.Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%
Key Insights Significantly high institutional ownership implies Cerus' stock price is sensitive to their trading...
Business WireCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CONCORD, Calif., March 26, 2024--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories
